Bronchitis
Bronchitis is an inflammation of the bronchi that causes coughing and can lead to symptoms like wheezing, shortness of breath, and chest pain; it can be either acute, often starting as an infection in the upper respiratory tract, or chronic, which is a form of COPD characterized by persistent bronchial irritation and mucus build-up.
Health Outcomes
- Accelerated Recovery of B Cell-Mediated Respiratory Immunity
- Altered Antibiotic Susceptibility
- Colonization of Nasopharynx or Adenoid Tissue
- Enhanced Antipneumococcal IgA Levels in BAL
- Enhanced Goblet Cell Function
- Enhanced Non-specific Immune Defense
- Enhanced Phagocytosis by Monocyte-Derived Dendritic Cells
- Enhanced Pulmonary Immune Response
- Enhanced Resistance to Infections
- Enhanced Resistance to Respiratory Infections
- Enhanced Resistance to Streptococcus Pneumoniae Infection
- Improved Airway Immune Response
- Improved Airway Mucosa Condition
- Improved Airway Secretion Clearance
- Improved Anti-infection Response
- Improved Asthmatic Condition
- Improved Chest X-Ray Finding
- Improved Clinical Symptoms of Influenza
- Improved Cure Rate on Day 3
- Improved Cure Rate on Day Four
- Improved Histopathological Findings in Lungs
- Improved Immune Mechanisms Against S. pneumoniae
- Improved Lung Function
- Improved Pneumococcal Infection Outcomes
- Improved Pulmonary Function
- Improved Resistance to Pneumococcal Respiratory Infection
- Improved Resistance to RSV Infection
- Improved Respiratory Immune Function
- Improved Respiratory Immunity
- Improved Respiratory Mucosal Barrier Function
- Improved Respiratory Tract Health
- Improved Serum Immunity
- Improved Vaccine-Specific Secretory IgA Levels in Saliva
- Increased Abundance of Goblet Cells
- Increased Anti-Pneumococcal Antibody Levels
- Increased Antibacterial Compound Production
- Increased Antibiotic Susceptibility
- Increased Antibiotic Use
- Increased Bacillus Spore Counts
- Increased Days Without Illness
- Increased Dispersal of Pathogenic Bacteria
- Increased Economic Burden Due to Higher Antibiotic Costs
- Increased Fever-Free Days
- Increased Incidence of Pulmonary Exacerbations
- Increased Incidence of Upper Respiratory Symptoms
- Increased Mucin Production
- Increased Mucin Secretion
- Increased Mucus Secretion
- Increased Post-Infection Lung Monocyte Levels
- Increased Resistance to Pneumococcal Infections
- Increased Respiratory Sensitization
- Inhibition of RSV Replication
- Managed Cystic Fibrosis
- Modulated Pulmonary Innate Immune Response
- Modulation of Pulmonary Innate Immune Function
- Nasopharyngeal Colonization
- No Significant Change in Inflammatory Responses
- Preserved Anti-pseudomonal Activity
- Prevention of Mucus Barrier Decline
- Reduced Airway Inflammation
- Reduced Airway Inflammation Score
- Reduced Airway Pathological Responses
- Reduced Antibiotic Duration
- Reduced Antibiotic Use
- Reduced Antibiotic Use Due to Infections
- Reduced Antibiotic and Antiviral Use
- Reduced Antimicrobial Use
- Reduced Bacterial Infection Severity
- Reduced Bacterial Load in Lungs
- Reduced Bronchitis Symptom
- Reduced Common Cold Incidence in Susceptible Populations
- Reduced Community-Acquired Infection
- Reduced Cough Duration
- Reduced Days on Antibiotic Therapy
- Reduced Duration of Acute Respiratory Infection
- Reduced Duration of Antibiotic Usage
- Reduced Duration of Respiratory Infection
- Reduced Duration of Respiratory Tract Infection Episode
- Reduced Duration of Respiratory Tract Infections
- Reduced Exposure to Harmful Substances
- Reduced Fever Duration During CID
- Reduced Frequency of Upper Respiratory Tract Infections
- Reduced Growth of Harmful Bacteria
- Reduced Harmful Bacterial Populations
- Reduced IL-5 Levels
- Reduced Impact of Gram-negative Microorganisms
- Reduced Incidence of Common Infections
- Reduced Incidence of Infections
- Reduced Incidence of Influenza-like Illness
- Reduced Incidence of Respiratory Illness
- Reduced Infant Wheeze
- Reduced Inflammation in the Lower Respiratory Tract
- Reduced Lower Respiratory Infection
- Reduced Lung Damage
- Reduced Lung Histopathology Scores
- Reduced Lung Inflammation
- Reduced Lung Injury
- Reduced Lung Tissue Damage
- Reduced Mean Number of Infections per Child
- Reduced Mold Presence
- Reduced NO Secretion Induced by LPS
- Reduced Opportunistic Pathogenic Bacteria Levels
- Reduced PICU Discharge Time
- Reduced Pathogen Activity
- Reduced Pathogenic Bacterial Activity
- Reduced Pathogenic Colonies
- Reduced Pediatric Exacerbations
- Reduced Pediatric Intensive Care Unit Stay
- Reduced Postinfective Symptoms
- Reduced Pseudomonas aeruginosa-Induced Damage
- Reduced Pulmonary Free-CML
- Reduced RSV Replication
- Reduced RSV Viral Load in Lungs
- Reduced Respiratory Illness
- Reduced Respiratory Infections in Infants
- Reduced Respiratory Inflammation Severity
- Reduced Respiratory Pathogen Load
- Reduced Respiratory Symptom Days
- Reduced Respiratory Symptoms
- Reduced Respiratory Tract Infection
- Reduced Respiratory Tract Infection Episodes
- Reduced Respiratory Tract Infections
- Reduced Risk of Antimicrobial Resistance
- Reduced Risk of Prolonged Respiratory Infections
- Reduced Severity of Acute Respiratory Infection
- Reduced Sick Leave Days
- Reduced Staphylococcus aureus Colonization
- Reduced Streptococcus pneumoniae in Lung
- Reduced Tracheitis
- Reduced Treatment Duration
- Reduced Upper Respiratory Tract Infection Treatment Duration
- Reduced Virus Titers in Bronchoalveolar Lavage Fluid
- Reduced Wheezing